Today, we discuss three must-own stocks as major Wall Street indices reach new highs. The rise in share prices of technology stocks and supportive economic data hinting at potential Federal Reserve policy easing have contributed to investor optimism. So far in 2024, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY), which tracks the S&P 500 index, is up 13%. Similarly, the Invesco QQQ Trust ETF (NYSEARCA:QQQ), which tracks the Nasdaq-100, rose 14% since January, while the SPDR Dow Jones Industrial Average ETF Trust ...

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced preliminary safety and efficacy results from its ...

AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.AstraZeneca (AZN -0.70%), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of achieving annual revenue exceeding $45 billion by 2023.This target was met with skepticism by Wall Street and dismissed as excessively optimistic. Contrary to these ...

HAMILTON, ON and BOSTON, May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the "Shareholders"), held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Cor ...

AstraZeneca (AZN) reported overall survival (OS) data from a late-stage study, which evaluated its partner Daiichi Sankyo’s investigational candidate, datopotamab deruxtecan (Dato-DXd), compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Docetaxel is the current standard-of-care chemotherapy for this patient population.Though the OS results numerically favored Dato-DXd, it failed to achieve statistical significance in the overall population of the phas ...

Both businesses have road maps for the future, but one is better.As two of the world's largest and most prolific drugmakers, Pfizer (PFE -1.38%) and AstraZeneca (AZN -0.87%) both have grand visions for how to grow even larger over the coming years. And with billions of dollars devoted to research and development, it's almost certain to lead to the discovery of new golden-goose medicines that should enrich shareholders.But for investors, the details about how those billions will be spent, and how those winni ...

Its new strategic roadmap aims to catapult the company forward.AstraZeneca (AZN -2.44%) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global biopharma sector, and its investors could potentially be wealthier too.But that doesn't make it the right choice for everyone, so it's important to dive into the details of exactly what it's setting out to do. Let's start by putting this plan into cont ...

•  Cellectis announced completion of the additional equity investment of $140M by AstraZeneca •  Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 •  Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided busin ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology. Under the terms of the agreement, Nona Biosciences shall receive US$19 milli ...